Unmet needs in treating ovarian cancer in geriatric patients - VJOncology Felix Hilpert, MD, Krankenhaus Jerusalem, Hamburg, Germany, gives an overview of treatment gaps in elderly and frail patients with ovarian...

⭐ Felix Hilpert, MD, stresses that age/frailty shouldn’t preclude ovarian cancer therapy: chemo & surgery can extend survival in older pts:

🎥 buff.ly/MUxPkAI

#ESMOGynae25 #GynOnc #GyncSM

ROSELLA trial: relacorilant plus nab-paclitaxel in ovarian cancer - VJOncology Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy, discusses secondary endpoint findings from the Phase...

🎥 Domenica Lorusso, MD, PhD, reports relacorilant + nab-paclitaxel improved PFS & OS in platinum-resistant ovarian cancer w/ consistent safety:

➡️https://buff.ly/M7ojYej

#ESMOGynae25 #GynOnc #GyncSM #CTSM #TrialUpdate

Assessing ctDNA to detect mutations in ovarian cancer in the RAMP 201 trial - VJOncology Alberto Farolfi, MD, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Dino Amadori, Meldola, Italy, describes the limitations of...

🎥 Alberto Farolfi, MD, reports ctDNA did not align with tissue molecular analysis in the RAMP 201 trial for cervical cancer. Highlights limitations of ctDNA as a reliable biomarker in this setting:

➡️ buff.ly/pQUGuhR

#ESMOGynae25 #GynOnc #Gyncsm

Can we currently sequence ADCs in ovarian cancer? - VJOncology Angeles Secord, MD, Duke Cancer Institute, Durham, NC, comments on the limitations of sequencing antibody-drug conjugated (ADCs) in ovarian cancer,...

🎥 Angeles Secord, MD, from @dukehealth.bsky.social addresses sequencing challenges of ADCs in ovarian cancer. With FDA approvals for mirvetuximab soravtansine and T-DXd, trials are essential for guiding target and payload choices.

🔗https://buff.ly/q23sXHU

#ESMOGynae25 #Gyncsm #GynOnc #ImmunoOnc

TRUST: optimal timing of surgical therapy in advanced ovarian cancer - VJOncology Christina Fotopoulou, MD, PhD, Imperial College London, London, UK, discusses the TRUST study (NCT02828618), a prospective randomized trial on the...

⏱️Delaying interval surgery after 6 cycles of NAC in advanced ovarian cancer doesn't worsen OS or PFS, per new data shared by Prof. Christina Fotopoulou at #ESMOGynae25. Timing may depend more on clinical context than chemo cycle

➡️ buff.ly/ReORMEN

@myesmo.bsky.social #GynOnc #GyncSM

June is #UterineCancerAwareness month.

A study presented at #ESMOGynae25 on #EndometrialCancer reveals that molecular subtyping using IHC + NGS identifies targetable alterations, influencing treatment. Results highlight the need for advanced diagnostics and updated guidelines.

20 Posts Not to Miss from ESMO Gynaecological Cancers Congr The 16th ESMO Gynaecological Cancers Congress 2025 was held in Florence, Italy, from June 19 to 21, uniting oncologists, researchers, and healt

20 Posts Not to Miss from ESMO Gynaecological Cancers Congress 2025
@myesmo.bsky.social

oncodaily.com/societies/20...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOGynae25 #GynOnc

Final PICCOLO Data Underscore Mirvetuximab Soravtansine’s Efficacy in Later-Line Frα+ Platinum-Sensitive Ovarian Cancer Mirvetuximab soravtansine continues to show efficacy and safety in final analysis of the phase 2 PICCOLO study.

Final PICCOLO Data Underscore Mirvetuximab Soravtansine’s Efficacy in Later-Line Frα+ Platinum-Sensitive Ovarian Cancer
#OvarianCancer #ESMOGynae25 @myesmo.bsky.social
www.onclive.com/view/final-p...

Research presented at #ESMOGynae25 evaluated the expression of five #ADC targets to assess their potential applicability in #OvarianCancer.

Findings reveal targetable alterations, that could lead to better therapeutic options and improved patient outcomes.

A thought-provoking presentation by Felix Hilpert at #ESMOgynae25 highlighting the substandard treatment of women older than 75 years with ovarian cancer.

Raludotatug Deruxtecan Shows Activity in Platinum-Sensitive Ovarian Cancer Raludotatug deruxtecan showed promising clinical activity in patients with heavily pretreated, platinum-sensitive ovarian cancer.

Raludotatug Deruxtecan Shows Activity in Platinum-Sensitive Ovarian Cancer @stephensoncancer.bsky.social @myesmo.bsky.social #ESMOGynae25 #oncolology www.onclive.com/view/raludot...

Challenging ageism in #GynaecologicCancer. In an Opinion piece in the #ESMODailyReporter, Elene Mariamidze discusses presentations at #ESMOGynae25 that highlight suboptimal treatment of older women despite effective treatments irrespective of age.

🔗 buff.ly/W84bpwm

#ESMOGynae25: Findings from the PICCOLO trial confirmed the efficacy of mirvetuximab soravtansine-gynx in heavily pretreated patients with FRα-positive platinum-sensitive #OvarianCancer regardless of HRD status.

Read more in the #ESMODailyReporter

🔗 buff.ly/dejbie1

#ESMOGynae25: Relacorilant plus nab-paclitaxel resulted in significantly prolonged PFS and clinically meaningful OS improvements in the ROSELLA #ClinicalTrial in platinum-resistant #OvarianCancer.

More in the #ESMODailyReporter

🔗 buff.ly/Yscy6cG

#ESMOGynae25: An analysis of the BEATcc trial revealed similar survival benefits with atezolizumab plus chemotherapy and bevacizumab regardless of PD-L1 status in untreated recurrent/metastatic #CervicalCancer.

Read more in the #ESMODailyReporter

🔗 buff.ly/hFVITc8

An analysis presented at #ESMOGynae25 highlighted distinct patterns of expression of different antibody–drug conjugate (ADC) targets in high-grade serous #OvarianCancer samples.

Further details in the #ESMODailyReporter

🔗 ow.ly/Arkz50Wcf1g

#ADC

🙌 #ESMOGynae25: N. Colombo, B. Monk and A. Oaknin welcome you to this international, multidisciplinary meeting solely focused on gynaecological malignancies.

🔗 buff.ly/8uNLub5

Join for ESMOGynae25 to Be Part of an International Exchange of Knowledge and Innovation in Gynaecological Oncology - ESMO - OncoDaily Join for ESMOGynae25 to Be Part of an International Exchange of Knowledge and Innovation in Gynaecological Oncology - ESMO / cancer, ESMO, ESMO - Eur.

Join ESMOGynae25 to Be Part of an International Exchange of Knowledge and Innovation in Gynaecological Oncology – ESMO
@myesmo.bsky.social

oncodaily.com/blog/esmogyn...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMOGynae25 #ESMO #GynOnc

📣 #ESMOGynae25: Last 24 hours to register and save! Network. Collaborate. Help us advance care.

⏰ Late registration deadline: 21 May 2025

🔗 buff.ly/lQjBCpd

📣 #ESMOGynae25: Last days to register and save! Be part of the conversation that is shaping the future of gynaecological malignancies.

⏰ Late registration deadline: 21 May 2025

🔗 buff.ly/ITSE6Hk

I'll be in Vienna next month at #ESMOGynae25 and I'm very happy to meet Lancet authors and reviewers to discuss ongoing research and how the Lancet group can help publish your work.

Are you attending the ESMO Gynaecological Cancers Congress 2025? #ESMOGynae25
Our Deputy Editor, Sarah Passey, invites you to reach out with enquiries.
Discover the reach and impact that Lancet authors can benefit from when publishing with us ➡️ bit.ly/4lf4X5X
#womenshealth #obgyn

 📣 #ESMOGynae25: Advance your practice and make a meaningful impact in the lives of women with gynaecological cancers.

⏰ Late registration deadline: 21 May 2025

🔗 buff.ly/JK8v9xh

📣 #ESMOGynae25: Watch R. Coleman, I. Colombo and P. Harter comment on the role of immunotherapy for gynaecological cancers

🎥 buff.ly/lXqoaNm

⏰ Register by 15 April to benefit from the most advantageous fees.

🔗 buff.ly/uMlgbuC